The pharmaceutical industry and congressional Republicans are expected to look for ways to slow implementation of the drug pricing law and could push some smaller bipartisan pricing reforms in 2023, while the Biden administration and Democrats are expected to focus on ensuring smooth implementation of Medicare’s new drug price negotiation authority, sources say. A handful of policies, such as creating more transparency and reforming business practices commonly used by pharmacy benefit managers and insurers, could advance this Congress with bipartisan...